logo
logo

Intelligencia Raises $12M To Reduce The Risk Of Clinical Research, Improve R&Amp;D Productivity, And Accelerate Scientific Breakthroughs

Intelligencia Raises $12M To Reduce The Risk Of Clinical Research, Improve R&Amp;D Productivity, And Accelerate Scientific Breakthroughs

08/10/21, 9:59 AM
Money raised
$12 million
Intelligencia, whose AI-driven software platform enables pharmaceutical and biotechnology companies to revolutionize the drug development process and reduce risk, has raised $12M in order to continue to expand its product offering and customer base. Healthtech investor MTIP led the oversubscribed Series A round, joined by several of the company’s existing investors, including Big Pi Ventures and Synetro Group. ZS, a global professional services firm that leverages deep analytics and biopharmaceutical industry expertise to help companies and their customers thrive, has also participated in this round.

Company Info

Company
Intelligencia
Additional Info
Intelligencia is an AI-driven technology company that focuses on minimizing the risk of drug development and enabling external innovation. It transforms how R&D and Business Development executives think about and assess the risk of clinical development programs and enables them to make more informed and data-driven decisions as they evaluate their own pipelines and/or external opportunities. Visit www.intelligencia.ai to learn more.